Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
FiercePharma1d
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Vertex Pharmaceuticals price target raised to $520 from $460 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...
Vertex stock price target lifted to $444 by Bernstein
Bernstein SocGen Group adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. With a ...
Vertex Pharmaceuticals price target raised to $459 from $450 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...
Vertex Pharmaceuticals Posts Higher 4Q Revenue
For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
Vertex Q4 revenue beats Street, guidance in line with consensus
Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...